» Articles » PMID: 35073877

Importance of Circulating Adipocytokines in Multiple Myeloma: a Systematic Review and Meta-analysis Based on Case-control Studies

Overview
Publisher Biomed Central
Specialty Endocrinology
Date 2022 Jan 25
PMID 35073877
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Adipocytes and their products, adipocytokines, play important roles in the generation and development of multiple myeloma (MM). Studies have demonstrated some adipocytokines to be associated with MM, although those results are controversial. Therefore, we conducted a meta-analysis to verify the association of adipocytokines with MM.

Methods: We performed a systematic retrieval of literature published prior to 26 October 2021. Standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated to evaluate pooled effects. Subgroup analysis and meta-regression analysis were conducted to detect sources of heterogeneity. Sensitivity analysis was performed to evaluate the stability of the study. Publication bias was assessed by funnel plots and Egger's linear regression test.

Results: Ten eligible studies with 1269 MM patients and 2158 controls were included. The pooled analyses indicated that circulating leptin levels of MM patients were significantly higher than control levels (SMD= 0.87, 95%CI: 0.33 to 1.41), while the circulating adiponectin levels in MM patients were significantly lower than controls with a pooled SMD of -0.49 (95%CI: -0.78 to -0.20). The difference of circulating resistin levels were not significant between MM patients and controls (SMD= -0.08, 95%CI: -0.55 to 0.39). Subgroup analysis and meta-regression analysis found that sample size, age, and sex were possible sources of heterogeneity. Sensitivity analysis demonstrated our pooled results to be stable.

Conclusion: Decreased circulating adiponectin and increased leptin levels were associated with the occurrence and development of MM. Adiponectin and leptin may be potential biomarkers and therapeutic targets for MM.

Citing Articles

Effect of adipose tissue on the development of multiple myeloma.

Stanislawowski M Mol Biol Rep. 2024; 52(1):74.

PMID: 39708277 DOI: 10.1007/s11033-024-10174-8.


Body size and risk of multiple myeloma in the Black Women's Health Study.

Kataria Y, Niharika Pillalamarri B, Zirpoli G, Szalat R, Palmer J, Bertrand K Br J Cancer. 2024; 130(5):830-835.

PMID: 38212484 PMC: 10912597. DOI: 10.1038/s41416-023-02571-w.


Obesity as a risk factor for multiple myeloma: insight on the role of adipokines.

Tie W, Ma T, Yi Z, Liu J, Li Y, Bai J Pathol Oncol Res. 2023; 29:1611338.

PMID: 37637774 PMC: 10447903. DOI: 10.3389/pore.2023.1611338.


Calorie restriction has no effect on bone marrow tumour burden in a Vk*MYC transplant model of multiple myeloma.

Bradey A, Fitter S, Duggan J, Wilczek V, Williams C, Cheney E Sci Rep. 2022; 12(1):13128.

PMID: 35908046 PMC: 9338941. DOI: 10.1038/s41598-022-17403-9.

References
1.
Gu L, Cao C, Fu J, Li Q, Li D, Chen M . Serum adiponectin in breast cancer: A meta-analysis. Medicine (Baltimore). 2018; 97(29):e11433. PMC: 6086546. DOI: 10.1097/MD.0000000000011433. View

2.
Wan X, Wang W, Liu J, Tong T . Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014; 14:135. PMC: 4383202. DOI: 10.1186/1471-2288-14-135. View

3.
Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai Y . Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013; 122(7):1243-55. PMC: 3744991. DOI: 10.1182/blood-2013-02-483511. View

4.
Wang C, Wang P, Hsieh Y, Lo S, Lee Y, Chen Y . Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 2017; 37(5):589-600. DOI: 10.1038/onc.2017.357. View

5.
Hofmann J, Birmann B, Teras L, Pfeiffer R, Wang Y, Albanes D . Low Levels of Circulating Adiponectin Are Associated with Multiple Myeloma Risk in Overweight and Obese Individuals. Cancer Res. 2016; 76(7):1935-41. PMC: 4878138. DOI: 10.1158/0008-5472.CAN-15-2406. View